Development of eIF2B Activator ABBV-CLS-7262 as a Novel Treatment for Vanishing White Matter Disease (P2-8.001)
Amos Baruch, Paul Malik, Anu Gopathi, Ellen Ingalla et autres
0 citationsNeurology
Ellen Ingalla
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
75Publications signalées
1350Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Protein Degradation and InhibitorsBladder and Urothelial Cancer TreatmentsFibroblast Growth Factor ResearchMultiple Myeloma Research and TreatmentsPulmonary Hypertension Research and Treatments
Publications récentes
Physiologically‐based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans
Anjani Ganti, Sijia Yu, Danielle Sharpnack, Ellen Ingalla et autres
6 citationsBiopharmaceutics & Drug Disposition
Supplementary Figure 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Data from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Figure 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Table 1 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Figure 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Figure 4 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Table 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Figure 5 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.